Hikma Pharmaceuticals USA Inc. et al. vs Amarin Pharmaceuticals Ireland Limited

Notice: refund approved

Petitioners' Request For Refund Of Post-Institution Fees

Termination Decision: Settlement Prior to Institution of Trial

Joint Request That Agreement Be Treated As Business Confidential Information And Kept Separate Under 35 U.S.C. �� 317(b)

EXPUNGED

Joint Motion To Terminate

Ex. 1050-Settlement Agreement (Business Confidential)

Patent Owner's Mandatory Notices

Patent Owner's Power of Attorney

Notice: Notice filing date accorded

Ex. 1001 - U.S. Patent No. 8,642,077 B2 to Manku et al.

Ex. 1003 - WO 2007/142118 to Yokoyama et al. (2007) (certified English translation)

Ex. 1004 - Mori et al., Purified Eicosapentaenoic and Docosahexaenoic Acids Have Differential Effects on Serum Lipids and Lipoproteins, LDL Particle Size, Glucose, and Insulin in Mildly Hyperlipidemic Men, 71 Am. J. Clinical Nutri. 1085

Ex. 1005 - Yokoyama et al., Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): a Randomized Open- Label, Blinded Endpoint Analysis, 369 Lancet 1090 (2007)

Ex. 1006 - Satoh et al., Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C-Reactive Protein in Metabolic Syndrome, 30:1 Diabetes Care 144 (2007)

Ex. 1007 - Grimsgaard et al., Highly Purified Eicosapentaenoic Acid and Docosahexaenoic Acid in Humans Have Similar Triacylglycerol-Lowering Effects but Divergent Effects on Serum Fatty Acids, 66 Am. J. Clin. Nutr. 649 (1997)

Ex. 1008 -Third Report of the National Cholesterol Education Program (N CEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111) Final Report (Sept. 2002) Part 1

Ex. 1008 -Third Report of the National Cholesterol Education Program (N CEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111) Final Report (Sept. 2002) Part 2

Ex. 1008 - Third Report of the National Cholesterol Education Program (N CEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111) Final Report (Sept. 2002) Part 3

Ex. 1009 - Plaintiffs' Corrected Post-Trial Proposed Findings of Fact and Conclusions of Law (Feb. 27, 2020) from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525, D.I. 377, 510 (D. Nev.)

Ex. 1010 - Day 2 (Jan. 14, 2020) Trial Transcript from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) (Testimony of Dr. Budoff)

Ex. 1011 -Vital and Health Statistics, Serum Lipids of Adults 20-74 Years: United States, 1976-80, 11:242, Nat'l Health Survey, U.S. Dept. Health & Human Servs. (Mar. 1993)

Ex. 1012 - Schmidt et al., Lipid evaluation in HIV-1-positive patients treated with protease inhibitors, 4 Antiviral Ther. 163-170 (1999)

Ex. 1014 - Lovaza, Physicians' Desk Reference 2699 (62d ed. 2007)

Ex. 1015 - Nozaki et al., Effects of Purified Eicosapentaenoic Acid Ethyl Ester on Plasma Lipoproteins in Primary Hypercholesterolemia, 62 Int'l J. Vitamin & Nutr. Res. 256- 60 (1992)

Ex. 1016 - Shinozaki et al., The Long-Term Effect of Eicosapentaenoic Acid on Serum Levels of Lipoprotein (a) and Lipids in Patients with Vascular Disease, 2(2) J. Atheroscl. Thromb. 107-09 (1996)

Ex. 1017 - Joint Stipulations of Fact from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.)

Ex. 1018 - Day 7 (Jan. 28, 2020) Trial Transcript from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) (Testimony of Dr. Toth)

Ex. 1020 -Plaintiffs' Infringement Contentions from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.)

Ex. 1019 -Plaintiffs' Validity Contentions from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) Part 1

Ex. 1019 -Plaintiffs' Validity Contentions from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) Part 2

Ex. 1019 -Plaintiffs' Validity Contentions from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) Part 3

Ex. 1019 -Plaintiffs' Validity Contentions from Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., No. 16-2525 (D. Nev.) Part 4

Ex. 1021 - Plaintiffs' Opposition to Motion to Dismiss from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.)

Ex. 1022 - Plaintiffs' First Amended Complaint from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.) (D.I.17)

Ex. 1023 - Exhibit U to Plaintiffs' First Amended Complaint,Ballantyne et al., Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients with Persistent High Triglycerides

Ex. 1024 - Exhibit V to Plaintiffs' First Amended Complaint, Bhatt et al., Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, 380:1 N. Engl. J. Med. 11-22 (2018)

Ex. 1025 -Amarin Response to U.S. Patent Office re U.S. Patent Application No. 17/768,906 (Aug. 26, 2013)

Ex. 1026 - Davidson et al., Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients

Ex. 1027 - Saito et al., Effects of EPA on Coronary Artery Disease in Hypercholesterolemic Patients with Multiple Risk Factors: Sub-Analysis of Primary Prevention Cases from the Japan EPA Lipid Intervention Study (JELIS)

Ex. 1028 - Notice of Allowability from U.S. Patent Office re U.S. Patent Application No. 13/768,906 (Sept. 30, 2013)

Ex. 1029 - FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting regarding ANCHOR trial (Oct. 16, 2013)

Ex. 1030 -U.S. Patent Office Interview Summary re U.S. Patent Application No. 13/614,111 (Dec. 12, 2012)

Ex. 1031 - Amarin Supplemental Response to U.S. Patent Office re U.S. Patent Application No. 13/614,111 (Jan. 11, 2013)

Ex. 1032 - Notice of Allowability from U.S. Patent Office re U.S. Patent Application No. 13/614,111 (Feb. 11, 2013)

Ex. 1033 - Vascepa Label (12/2019)

Ex. 1034 - World Health Organization Memorandum, Classification of Hyperlipoproteinemias, 43:891, 501-508 (1972)

Ex. 1035 - Declaration of C. Rosebraugh from Amarin Pharma, Inc. et al. v. U.S. F.D.A. et al., No. 15-3588 (S.D.N.Y.)

Ex. 1036 - Scheduling Order from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.)

Ex. 1037 - Hikma's Motion to Dismiss from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.)

Ex. 1038 - Office Action from U.S. Patent Office re U.S. Patent Application No. 13/768,906 (May 24, 2013)

Ex. 1039 -Original Japanese version of WO 2007/142118 to Yokoyama et al.

Ex. 1040 - U.S. Patent No. 6,384,077 to Peet et al.

Ex. 1041 - U.S. Patent No. 6,479,544 to Horrobin

Ex. 1042 - U.S. Patent No. 7,119,118 to Peet et al.

Ex. 1043 - Amarin Reports Fourth Quarter and Full Year 2004 Results Report

Ex. 1044 - U.S. Patent Application Publication No. 2007/0021504 A1 to Yokoyama et al.

Ex. 1045 - Yokoyama et al., Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: Rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS

Ex. 1046 - Joint Claim Construction Chart from Amarin Pharma, Inc. et al. vs. Hikma Pharms. USA Inc. et al., C.A. No. 20-1630 (D. Del.)

Ex. 1047 - Curriculum vitae of Edward A. Fisher

Ex. 1048 -Lipitor (atorvastatin calcium) Label (09/2007)

Ex. 1049 - Crestor (rosuvastatin calcium) Label (11/2007)

Petitioner's HIKMA Power of Attorney

Ex. 1002 - Expert Declaration of Edward A. Fisher, M.D., Ph.D., M.P.H.

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 1

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 2

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 3

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 4

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 5

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 6

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 7

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 8

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 9

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 10

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 11

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 12

Ex. 1013 - Expert Declaration of Sylvia Hall-Ellis, Ph.D. Part 13

IPR Petition '077